Tarsons Products
TARSONS NSE
Tarsons Products
HealthcareNSE: TARSONS BSE: 543399 Healthcare Equipment & Supplies
Key Fundamentals
MicrocapMedical EquipmentHealthcareMarket Cap
₹1,639 Cr
Volatility
Moderate
P/E Ratio
148.9
EBITDA
₹142 Cr
Return on Equity
2.26%
Debt to Equity
0.62
Book Value
₹119.29
EPS
₹8.01
52W High
₹375
52W Low
₹164.45
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
5- Stock is trading at 2.61 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Company has a low return on equity of 4.68% over last 3 years.
- Company might be capitalizing the interest cost
Growth Rate
Revenue Growth
9.38% lower than
3Y
Net Income Growth
-52.01% higher than
3Y
Cash Flow Change
3.71% lower than
3Y
ROE
-52.12% lower than
3Y
ROCE
-32.11% higher than
3Y
EBITDA Margin (Avg.)
2.55% higher than
3Y
Quarterly Results
| Particulars | Dec 2021 | Mar 2022 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 70.66 | 84.94 | 61.79 | 106 | 84.8 | 99.25 | 95.68 | 113 | 91.36 | 102 | 108 | 121 | 110 |
| Expenses | 37.52 | 40.61 | 38.91 | 75.48 | 66.04 | 73.94 | 66.04 | 75.67 | 66.66 | 74.88 | 76.37 | 86.66 | 84.25 |
| Operating Profit | 33.14 | 44.33 | 22.88 | 30.24 | 18.76 | 25.31 | 29.64 | 37.02 | 24.7 | 27.45 | 31.52 | 34.27 | 25.99 |
| OPM % | 46.9% | 52.19% | 37.03% | 28.6% | 22.12% | 25.5% | 30.98% | 32.85% | 27.04% | 26.82% | 29.21% | 28.34% | 23.58% |
| Other Income | 2.46 | 2.58 | 3.24 | 3.38 | 2.91 | 8.43 | 0.85 | 3.78 | 3.34 | 5.8 | 7.07 | 6.83 | 5.98 |
| Interest | 1.37 | 0.45 | 2.51 | 4.25 | 4.32 | 4.84 | 5.03 | 5.2 | 5.07 | 5.18 | 6.05 | 6.25 | 6.27 |
| Depreciation | 5.35 | 7.24 | 10.06 | 12.33 | 11.03 | 14.03 | 17.41 | 20.03 | 19.94 | 22.48 | 25.04 | 29.08 | 27.02 |
| PBT | 28.88 | 39.22 | 13.55 | 17.04 | 6.32 | 14.87 | 8.05 | 15.57 | 3.03 | 5.59 | 7.5 | 5.77 | -1.32 |
| Tax % | 25.66% | 24.89% | 26.72% | 39.5% | 36.39% | 30.8% | 34.66% | 34.49% | 41.25% | 40.61% | 32.93% | 27.56% | 9.09% |
| Net Profit | 21.47 | 29.46 | 9.93 | 10.32 | 4.02 | 10.29 | 5.26 | 10.2 | 1.78 | 3.32 | 5.04 | 4.18 | -1.44 |
| EPS in Rs | 4.04 | 5.54 | 1.87 | 1.94 | 0.76 | 1.93 | 0.99 | 1.92 | 0.33 | 0.62 | 0.95 | 0.79 | -0.27 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 229 | 301 | 296 | 392 | 423 | 441 |
| Expenses | 125 | 148 | 196 | 282 | 304 | 322 |
| Operating Profit | 103 | 153 | 100 | 111 | 118 | 119 |
| OPM % | 45% | 51% | 34% | 28% | 28% | 27% |
| Other Income | 5 | 8 | 11 | 16 | 23 | 26 |
| Interest | 3 | 4 | 10 | 20 | 23 | 24 |
| Depreciation | 14 | 22 | 40 | 62 | 97 | 104 |
| PBT | 92 | 135 | 61 | 45 | 22 | 18 |
| Tax % | 25% | 25% | 30% | 34% | 35% | — |
| Net Profit | 69 | 101 | 43 | 30 | 14 | 11 |
| EPS in Rs | 3,583 | 18.92 | 8.01 | 5.6 | 2.69 | 2.09 |
| Div. Payout % | 0% | 0% | 25% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity Capital | 0.19 | 11 | 11 | 11 | 11 |
| Reserves | 244 | 479 | 602 | 620 | 624 |
| Borrowings | 34 | 22 | 269 | 339 | 393 |
| Other Liabilities | 18 | 33 | 90 | 111 | 158 |
| Total Liabilities | 296 | 544 | 972 | 1,080 | 1,186 |
| Fixed Assets | 120 | 189 | 336 | 536 | 733 |
| CWIP | 22 | 32 | 267 | 233 | 159 |
| Investments | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 153 | 323 | 369 | 311 | 295 |
| Total Assets | 296 | 544 | 972 | 1,080 | 1,186 |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating | 68 | 83 | 103 | 114 | 118 |
| Investing | -64 | -138 | -285 | -145 | -129 |
| Financing | -27 | 130 | 136 | 39 | 9 |
| Net Cash Flow | -23 | 75 | -47 | 8 | -2 |
| Free Cash Flow | 6 | -48 | -81 | -37 | -7 |
| CFO/OP | 89 | 77 | 121 | 117 | 107 |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Debtor Days | 75 | 79 | 96 | 74 | 74 |
| Inventory Days | 277 | 478 | 572 | 355 | 341 |
| Days Payable | 35 | 75 | 65 | 44 | 53 |
| Cash Conversion Cycle | 317 | 482 | 602 | 385 | 361 |
| Working Capital Days | 108 | 150 | -1 | 38 | -20 |
| ROCE % | — | 35% | — | 7% | 5% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Tarsons Products insights
52 extracted metrics + investor summaries across FY20–FY26.
Documents
1
Clarification sought from Tarsons Products Ltd
18 Jun - Exchange has sought clarification from Tarsons Products Ltd on June 18, 2026 with reference to significant movement in price, in order to ensure that investors … 18 Jun - Exchange has sought clarification from Tarsons Products Ltd on June 18, 2026 with reference to significant movement in price, in order to ensure that investors …
2
Announcement under Regulation 30 (LODR)-Change in Management
14 Apr - Tarsons appoints Mani Kalyan Dusi as Head-Revenue (India & APAC), joining by May 20, 2026. 14 Apr - Tarsons appoints Mani Kalyan Dusi as Head-Revenue (India & APAC), joining by May 20, 2026.
3
Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015
9 Apr - Tarsons completed EUR 300,000 equity infusion in Singapore subsidiary for loan repayment and expenses. 9 Apr - Tarsons completed EUR 300,000 equity infusion in Singapore subsidiary for loan repayment and expenses.
4
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
9 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026 9 Apr - Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026
3
Notice Of The 43Rd Annual General Meeting Of The Company For The Financial Year Ended March 31 2026 2 Sept 2026
Intimation
4
Notice Of The 43Rd Annual General Meeting Of The Company For The Financial Year Ended March 31 2026 2 Sept 2026
Intimation
Frequently Asked Questions about Tarsons Products
What does Tarsons Products Ltd do?
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical com...
Where is Tarsons Products Ltd (TARSONS) listed?
Tarsons Products Ltd trades as TARSONS on the NSE and under code 543399 on the BSE.
Which sector does Tarsons Products Ltd belong to?
Tarsons Products Ltd is classified under the Healthcare sector, in the Healthcare Equipment & Supplies industry.
What is the market capitalisation of Tarsons Products Ltd?
Tarsons Products Ltd has a market capitalisation of ₹1,639 Cr, which places it in the Small Cap band.
What is the PE ratio of Tarsons Products Ltd?
Tarsons Products Ltd trades at a PE ratio of 148.90, on earnings per share of ₹8.01, against a book value of ₹119.29 per share.
What is the 52-week high and low of Tarsons Products Ltd?
Over the last 52 weeks Tarsons Products Ltd has traded between ₹164.45 and ₹375.
Does Tarsons Products Ltd pay dividends?
Tarsons Products Ltd has a dividend yield of 0.63%.
What is the Return on Equity (ROE) of Tarsons Products Ltd?
Tarsons Products Ltd reported a return on equity of 2.26%. Its debt-to-equity ratio is 0.62.
Company Information
Tarsons Products Ltd. (TPL) is an Indian labware company engaged in the designing, development, manufacturing, and marketing of 'consumables', 'reusables' and 'others' including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, Contract Research Organizations, Diagnostic companies, and hospitals[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/TARSONS.md for Tarsons Products Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.